PATIENT-REPORTED OUTCOMES AND THEIR RELATIONSHIP WITH CLINICAL OUTCOMES IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL STUDY

被引：0

作者：

Cella, D. ^{[1
]}

Ritchie, E. ^{[2
]}

Fabbiano, F. ^{[3
]}

Pigneux, A. ^{[4
]}

Kanda, Y. ^{[5
]}

Ivanescu, C. ^{[6
]}

Pandya, B. ^{[7
]}

Shah, M., V ^{[8
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[2] Weill Cornell Med, New York, NY USA

[3] Azienda Osped Osped Riuniti Villa Sofia Cervello, Sicily, Italy

[4] Ctr Hosp Univ Bordeaux, Bordeaux, France

[5] Jichi Med Univ, Shimotsuke, Tochigi, Japan

[6] IQVIA, Amsterdam, Netherlands

[7] Astellas Pharma Global Dev Inc, Northbrook, IL USA

[8] Astellas Pharma US Inc, Northbrook, IL USA

来源：

VALUE IN HEALTH | 2019年 / 22卷

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PCN485

引用

页码：S531 / S531

页数：1

共 50 条

[21] Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Daver, Naval
Perl, Alexander E.
Maly, Joseph
Levis, Mark
Ritchie, Ellen
Litzow, Mark
McCloskey, James
Smith, Catherine C.
Schiller, Gary
Bradley, Terrence
Tiu, Ramon, V
Naqvi, Kiran
Dail, Monique
Brackman, Deanna
Siddani, Satya
Wang, Jing
Chyla, Brenda
Lee, Paul
Altman, Jessica K.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (35) : 4048 - +
[22] Preliminary Analysis Results of a Phase I Study of the FLT3 Inhibitor SKLB1028 in Patients with Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
Liu, Ting
Zhu, Huanling
Yao, Xuekun
Peng, Yueying
Wang, Yumei
Zhan, Guoning
Yuan, Jing
Ni, Shaonan
Qiao, Jie
Hu, Zijian
Lyu, Cheng
BLOOD, 2019, 134
[23] Outcomes in Patients with FLT3-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
Perl, Alexander E.
Larson, Richard A.
Podoltsev, Nikolai A.
Strickland, Stephen
Wang, Eunice S.
Atallah, Ehab
Schiller, GaryJ.
Martinelli, Giovanni
Neubauer, Andreas
Sierra, Jorge
Montesinos, Pau
Recher, Christian
Yoon, Sung-Soo
Maeda, Yoshinobu
Hosono, Naoko
Onozawa, Masahiro
Kato, Takayasu
Kim, Hee-Je
Hasabou, Nahla
Nuthethi, Rishita
Tiu, Ramon
Levis, Mark J.
TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (04):
[24] Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial
Smith, Catherine C.
Levis, Mark J.
Perl, Alexander E.
Martinelli, Giovanni
Neubauer, Andreas
Berman, Ellin
Montesinos, Pau
Baer, Maria R.
Larson, Richard A.
Chou, Wen-Chien
Yokoyama, Hisayuki
Recher, Christian
Yoon, Sung-Soo
Hill, Jason E.
Rosales, Matt
Bahceci, Erkut
BLOOD, 2019, 134
[25] Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
Perl, Alexander E.
Hosono, Naoko
Montesinos, Pau
Podoltsev, Nikolai
Martinelli, Giovanni
Panoskaltsis, Nicki
Recher, Christian
Smith, Catherine C.
Levis, Mark J.
Strickland, Stephen
Rollig, Christoph
Gross-Langenhoff, Marco
Chou, Wen-Chien
Lee, Je-Hwan
Yokoyama, Hisayuki
Hasabou, Nahla
Lu, Qiaoyang
Tiu, Ramon, V
Altman, Jessica K.
BLOOD CANCER JOURNAL, 2022, 12 (05)
[26] Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
Alexander E. Perl
Naoko Hosono
Pau Montesinos
Nikolai Podoltsev
Giovanni Martinelli
Nicki Panoskaltsis
Christian Recher
Catherine C. Smith
Mark J. Levis
Stephen Strickland
Christoph Röllig
Marco Groß-Langenhoff
Wen-Chien Chou
Je-Hwan Lee
Hisayuki Yokoyama
Nahla Hasabou
Qiaoyang Lu
Ramon V. Tiu
Jessica K. Altman
Blood Cancer Journal, 12
[27] Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
Naoko Hosono
Hisayuki Yokoyama
Nobuyuki Aotsuka
Kiyoshi Ando
Hiroatsu Iida
Takayuki Ishikawa
Kensuke Usuki
Masahiro Onozawa
Masahiro Kizaki
Kohmei Kubo
Junya Kuroda
Yukio Kobayashi
Takayuki Shimizu
Shigeru Chiba
Miho Nara
Tomoko Hata
Michihiro Hidaka
Shin-Ichiro Fujiwara
Yoshinobu Maeda
Yasuyoshi Morita
Mikiko Kusano
Qiaoyang Lu
Shuichi Miyawaki
Erhan Berrak
Nahla Hasabou
Tomoki Naoe
International Journal of Clinical Oncology, 2021, 26 : 2131 - 2141
[28] Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
Hosono, Naoko
Yokoyama, Hisayuki
Aotsuka, Nobuyuki
Ando, Kiyoshi
Iida, Hiroatsu
Ishikawa, Takayuki
Usuki, Kensuke
Onozawa, Masahiro
Kizaki, Masahiro
Kubo, Kohmei
Kuroda, Junya
Kobayashi, Yukio
Shimizu, Takayuki
Chiba, Shigeru
Nara, Miho
Hata, Tomoko
Hidaka, Michihiro
Fujiwara, Shin-Ichiro
Maeda, Yoshinobu
Morita, Yasuyoshi
Kusano, Mikiko
Lu, Qiaoyang
Miyawaki, Shuichi
Berrak, Erhan
Hasabou, Nahla
Naoe, Tomoki
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (11) : 2131 - 2141
[29] A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
Daver, Naval
Assi, Rita
Ravandi, Farhad
Garcia-Manero, Guillermo
Jabbour, Elias
DiNardo, Courtney D.
Kadia, Tapan M.
Ning, Jing
Nogueras-Gonzalez, Graciela
Pierce, Sherry
Gombos, Dan
Komblau, Steven
Konopleva, Marina
Kelly, Mary
Borthakur, Gautam
Zhang, Weiguo
Cortes, Jorge
Kantarjian, Hagop
Andreeffl, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S7 - S8
[30] a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
Daver, Naval
Assi, Rita
Garcia-Manero, Guillermo
Ravandi, Farhad
Borthakur, Gautam
Jabbour, Elias J.
DiNardo, Courtney D.
Kadia, Tapan
Ning, Jing
Gonzalez, Graciela Nogueras
Pierce, Sherry
Kelly, Mary
Zhang, Weiguo
Gombos, Dan
Kornblau, Steven
Konopleva, Marina
Cortes, Jorge E.
Kantarjian, Hagop M.
Andreeff, Michael
BLOOD, 2017, 130

← 1 2 3 4 5 →